DOCSLIB.ORG

Tanibirumab (CUI C3490677) Add to Cart

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. Check for active clinical trials using this agent. (NCI Thesaurus) Synonyms & Abbreviations: (see Synonym Details) tanibirumab TTAC-0001 External Source Codes: NCI Thesaurus Code C102877 (see NCI Thesaurus info) PDQ Closed Trial Search ID 738495 PDQ Open Trial Search ID 738495 (check for NCI PDQ open clinical trial info) Other Properties: Name Value Source DATE_FIRST_PUBLISHED 2012-08-13 PDQ DATE_LAST_MODIFIED 2012-08-29 PDQ FR 3 MSH HM D000911 MSH MDA 20120310 MSH NCI_THESAURUS_CODE C102877 PDQ ORIG_STY Drug/agent PDQ RN 0 MSH SC 1 MSH SOS targets VEGFR2 MSH SRC Arch Pharm Res. 2011 Aug;34(8):1223-6. MSH TERMUI T819268 MSH TERMUI T819269 MSH TH NLM (2012) MSH Additional Concept Data: (none) URL to Bookmark: https://ncim.nci.nih.gov/ncimbrowser/ConceptReport.jsp?dictionary=NCI Metathesaurus&code=C3490677 Synonym Details: Term Source Type Code tanibirumab MSH NM C570591 Tanibirumab NCI PT C102877 tanibirumab PDQ PT CDR0000738495 TTAC-0001 MSH PCE C570591 TTAC-0001 NCI CCN C102877 TTAC-0001 PDQ CON CDR0000738495 https://ncim.nci.nih.gov/ncimbrowser/pages/concept_details.jsf?dictionary=NCI%20Metathesaurus&code=C3490677&type=all 1/79 5/17/2018 NCI Metathesaurus Relationships with other NCI Metathesaurus Concepts: Parents | Children | Broader | Narrower | Siblings | Other Parent Concepts: Relationship Rel. Attribute Name Rel. Source Parent isa Monoclonal Antibodies NCI Parent Pharmaceutical Preparations PDQ Child Concepts: (none) Broader Concepts: Relationship Rel. Attribute Name Rel. Source Broader mapped_to Monoclonal Antibodies MSH Narrower Concepts: (none) Sibling Concepts: Relationship Rel. Attribute Name Rel. Source Sibling Abortifacient Agents CSP Sibling antagonists & inhibitors CSP Sibling Anti-Allergic Agents CSP Sibling Anti-Infective Agents CSP Sibling Anti-Inflammatory Agents CSP Sibling antiarthritic agent CSP Sibling antidiuretic CSP Sibling Antidote CSP Sibling Antimetabolites CSP Sibling Antineoplastic Agents CSP Sibling Antirheumatic Agents CSP Sibling Antispasmodic Agent CSP Sibling Biological Factors CSP Sibling Carcinogen CSP Sibling Cardiovascular Agents CSP Sibling Chelating Agents CSP Sibling Chemical Surfactants CSP Sibling Choleretic agent CSP Sibling Cryoprotective Agent CSP Sibling dental agent CSP Sibling Diuretic CSP Sibling expectorant/mucolytic CSP Sibling eye agent CSP Sibling Fertility Agents CSP Sibling Gastrointestinal Agents CSP Sibling Gout Suppressants CSP Sibling Hematologic Agents CSP Sibling hyperglycemic agent CSP Sibling Hypoglycemic Agents CSP Sibling Immunomodulators CSP Sibling Mitogens CSP Sibling Multidrug Resistance Modulator CSP Sibling Muscle relaxants CSP Sibling Mutagen CSP Sibling Neuromuscular Blocking Agents CSP Sibling neuropharmacologic agent CSP Sibling nonenzyme proteolytic agent CSP Sibling Oxytocics CSP Sibling Pesticide CSP Sibling Photosensitizing Agent CSP Sibling Progestins CSP Sibling psychopharmacologic agent CSP Sibling Pyrogen CSP Sibling Radioprotective Agent CSP Sibling Radiosensitizing Agent CSP Sibling stimulant/agonist CSP Sibling Teratogen CSP Sibling Tocolytic Agents CSP Sibling Vitamins CSP Sibling weight control agent CSP Sibling XomaZyme CSP Sibling Antibodies, Monoclonal, Murine-Derived MSH Sibling controlled substance MSH Sibling Cosmeceuticals MSH Sibling Counterfeit Drugs MSH Sibling Designer Drugs MSH Sibling Dosage Forms MSH Sibling Drugs, Chinese Herbal MSH Sibling Drugs, Essential MSH Sibling Drugs, Non-Prescription MSH https://ncim.nci.nih.gov/ncimbrowser/pages/concept_details.jsf?dictionary=NCI%20Metathesaurus&code=C3490677&type=all 2/79 5/17/2018 NCI Metathesaurus Sibling Drug Combinations MSH Sibling Generic Drugs MSH Sibling Humanized Monoclonal Antibody MSH Sibling infliximab MSH Sibling Investigational New Drugs MSH Sibling Materia Medica MSH Sibling Medical Marijuana MSH Sibling Nostrums MSH Sibling Pharmaceutical Preparations, Dental MSH Sibling Pharmaceutic Aids MSH Sibling Placebos MSH Sibling Plant Extracts MSH Sibling Prescription Drugs MSH Sibling Prodrugs MSH Sibling Single-Chain Variable Fragment MSH Sibling Solutions MSH Sibling Street Drugs MSH Sibling Veterinary Drugs MSH Sibling Xenobiotics MSH Sibling 3H1 Aluminum Hydroxide-Precipitated Anti-Idiotype Monoclonal Antibody NCI Sibling A33 monoclonal antibody NCI Sibling Abciximab NCI Sibling adalimumab NCI Sibling Adecatumumab NCI Sibling Agonistic Anti-CD40 Monoclonal Antibody ADC-1013 NCI Sibling Alpha-Beta T-Cell Receptor Antibody NCI Sibling Amatuximab NCI Sibling Anrukinzumab NCI Sibling Anti-A33 Monoclonal Antibody KRN330 NCI Sibling Anti-A5B1 Integrin Monoclonal Antibody PF-04605412 NCI Sibling Anti-AGS-16 Monoclonal Antibody AGS-16M18 NCI Sibling Anti-AGS-8 Monoclonal Antibody AGS-8M4 NCI Sibling Anti-ALK-1 Monoclonal Antibody PF-03446962 NCI Sibling Anti-alpha5beta1 Integrin Antibody MINT1526A NCI Sibling Anti-alphaVbeta3 Monoclonal Antibody EMD 525797 NCI Sibling Anti-amyloid Monoclonal Antibody NEOD001 NCI Sibling Anti-ANG2 Monoclonal Antibody MEDI-3617 NCI Sibling Anti-angiopoietin Monoclonal Antibody AMG 780 NCI Sibling Anti-AXL Monoclonal Antibody-MMAE Conjugate NCI Sibling Anti-B7-H3 Antibody DS-5573a NCI Sibling Anti-c-fms Monoclonal Antibody AMG 820 NCI Sibling Anti-c-KIT Monoclonal Antibody KTN0158 NCI Sibling Anti-c-Met Monoclonal Antibody ABT-700 NCI Sibling Anti-c-Met Monoclonal Antibody ARGX-111 NCI Sibling Anti-c-MET Monoclonal Antibody LY2875358 NCI Sibling Anti-C-met Monoclonal Antibody SAIT301 NCI Sibling Anti-CA19-9 Monoclonal Antibody 5B1 NCI Sibling Anti-CD122 Humanized Monoclonal Antibody Mik-Beta-1 NCI Sibling Anti-CD123 Monoclonal Antibody CSL360 NCI Sibling Anti-CD123 Monoclonal Antibody KHK2823 NCI Sibling Anti-CD157 Monoclonal Antibody MEN1112 NCI Sibling Anti-CD19 Antibody-drug Conjugate SGN-CD19B NCI Sibling Anti-CD19 Monoclonal Antibody NCI Sibling Anti-CD20 Monoclonal Antibody PRO131921 NCI Sibling Anti-CD20 Monoclonal Antibody SCT400 NCI Sibling Anti-CD20 Monoclonal Antibody TL011 NCI Sibling Anti-CD22 Monoclonal Antibody-MMAE Conjugate DCDT2980S NCI Sibling Anti-CD25-PBD Antibody-drug Conjugate ADCT-301 NCI Sibling Anti-CD25 Monoclonal Antibody NCI Sibling Anti-CD2 Monoclonal Antibody NCI Sibling Anti-CD30/CD16A Monoclonal Antibody AFM13 NCI Sibling Anti-CD30 Monoclonal Antibody MDX-1401 NCI Sibling Anti-CD30 Monoclonal Antibody XmAb2513 NCI Sibling Anti-CD33/CD3 BiTE Antibody AMG 330 NCI Sibling Anti-CD33 Monoclonal Antibody BI 836858 NCI Sibling Anti-CD37 Monoclonal Antibody BI 836826 NCI Sibling Anti-CD38 Monoclonal Antibody MOR03087 NCI Sibling Anti-CD3 Monoclonal Antibody NCI Sibling Anti-CD40 Monoclonal Antibody NCI Sibling Anti-CD44 Monoclonal Antibody RO5429083 NCI Sibling Anti-CD45 Monoclonal Antibody NCI Sibling Anti-CD45 Monoclonal Antibody AHN-12 NCI Sibling Anti-CD45 Monoclonal Antibody BC8 NCI Sibling Anti-CD47 Monoclonal Antibody CC-90002 NCI Sibling Anti-CD47 Monoclonal Antibody Hu5F9-G4 NCI Sibling Anti-CD4 Monoclonal Antibody NCI Sibling Anti-CD52 Monoclonal Antibody NCI Sibling Anti-CD5 Monoclonal Antibody NCI https://ncim.nci.nih.gov/ncimbrowser/pages/concept_details.jsf?dictionary=NCI%20Metathesaurus&code=C3490677&type=all 3/79 5/17/2018 NCI Metathesaurus Sibling Anti-CD6 Monoclonal Antibody NCI Sibling Anti-CD70 Antibody-drug Conjugate SGN-CD70A NCI Sibling Anti-CD70 Monoclonal Antibody ARGX-110 NCI Sibling Anti-CD70 Monoclonal Antibody MDX-1411 NCI Sibling Anti-CD73 Monoclonal Antibody BMS-986179 NCI Sibling Anti-CD73 Monoclonal Antibody MEDI9447 NCI Sibling Anti-CD7 Monoclonal Antibody NCI Sibling Anti-CD8 Monoclonal Antibody NCI Sibling Anti-CD98 Monoclonal Antibody IGN523 NCI Sibling Anti-CEA/Anti-HSG Bispecific Monoclonal Antibody TF2 NCI Sibling Anti-CEACAM1 Monoclonal Antibody CM-24 NCI Sibling Anti-CEA Antibody NCI Sibling Anti-CEA BiTE Monoclonal Antibody MEDI-565 NCI Sibling Anti-CLDN6 Monoclonal Antibody IMAB027 NCI Sibling Anti-CSF1R
Recommended publications
  • Amidotrizoic Acid/Barium Sulfate 1477 Imbalance Should Be Corrected Before Contrast Media Are Given

    Amidotrizoic Acid/Barium Sulfate 1477 Imbalance Should Be Corrected Before Contrast Media Are Given

    Amidotrizoic Acid/Barium Sulfate 1477 imbalance should be corrected before contrast media are given. management of adhesive small bowel obstruction;2 they allow pyloric stenosis or lesions that may predispose to obstruction. Particular care is needed in patients with multiple myeloma since identification of patients who require surgery and, although they Adequate hydration should be ensured after the procedure to pre- dehydration resulting from use of contrast media may cause pre- have not been shown to relieve obstruction, they may reduce vent severe constipation. cipitation of protein in the renal tubules, leading to anuria and length of hospital stay in patients treated without surgery. It is contra-indicated in patients with gastrointestinal perforation, fatal renal failure. 1. Murshed R, et al. Meconium ileus: a ten-year review of thirty-six and should be avoided, particularly when given rectally, in those Caution is also necessary in patients with severe hypertension, patients. Eur J Pediatr Surg 1997; 7: 275–7. at risk of perforation, such as patients with acute ulcerative colitis advanced cardiac disease, phaeochromocytoma, sickle-cell dis- 2. Abbas S, et al. Oral water soluble contrast for the management or diverticulitis and after rectal or colonic biopsy, sigmoidosco- of adhesive small bowel obstruction. Available in The Cochrane ease, or hyperthyroidism or epilepsy, and in debilitated, severely Database of Systematic Reviews; Issue 3. Chichester: John Wi- py, or radiotherapy. ill, very old, or very young patients. ley; 2007 (accessed 14/07/08). Uses and Administration Amidotrizoates and other hypertonic contrast media are neuro- Preparations Barium sulfate is used as a radiographic contrast medium toxic and should not be given intrathecally; patients with sub- (p.1474) for X-ray examination of the gastrointestinal tract in- arachnoid haemorrhage may be at risk with any intravascular BP 2008: Meglumine Amidotrizoate Injection; Sodium Amidotrizoate In- jection; volving single- or double-contrast techniques or computed tom- use.
  • Phase II Study of Hormone Therapy with Tamoxifen in Patients with Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET)

    Phase II Study of Hormone Therapy with Tamoxifen in Patients with Well Differentiated Neuroendocrine Tumors and Hormone Receptor Positive Expression (HORMONET)

    Phase II study of hormone therapy with tamoxifen in patients with well differentiated neuroendocrine tumors and hormone receptor positive expression (HORMONET) Time of researchers and respective Departments: Rachel Riechelmann (Main Investigador)1, Milton Barros 1, Marcos Camandaroba1,2, Virgilio Souza1,2, Celso Abdon Mello1, Paula Nicole3, Eduardo Nóbrega4, Ludmilla Chinen5, Marina De Brot6, Héber Salvador7. Departaments: 1- Clinical Oncology; 2- postgraduate student; 3- Radiology; 4- Nuclear Medicine; 5-International Research Center (CIPE); 6-Pathologic anatomy; 7- Abdomen Surgery AC Camargo Cancer Center - Brazil Registration Number on Institutional Research Ethics Committee: 2626/18 March,06,2019 Introduction Neuroendocrine tumors (NET) are rare neoplasms, but with increasing incidence and prevalence in the last decades. Although they may manifest in the most diverse tissues, the vast majority of cases will affect organs of the digestive tract and lung. At diagnosis, more than half of the cases present metastatic disease, and among patients with localized disease, up to one-third will have recurrence of the disease. Unfortunately, the minority of patients with metastatic disease are eligible for curative intent.1 Although there are many types of NET, they are often studied together as a group because their cells share common histological findings, have special secretory granules, and the ability to secrete bioactive amines and polypeptide hormones. Approximately 25 percent of the tumors present functional hormonal syndromes (situation of great morbidity for these patients), being the carcinoid syndrome, the most common one. From the molecular point of view, these neoplasias are largely dependent on the activation of the mTOR pathway and neoangiogenesis.2 Another striking feature of neuroendocrine cells is the expression of cell surface hormone receptors whose activation or blockade may exert an important regulatory function.
  • The National Drugs List

    The National Drugs List

    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
  • Specifications of Approved Drug Compound Library

    Specifications of Approved Drug Compound Library

    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
  • Ontario Drug Benefit Formulary Edition 43

    Ontario Drug Benefit Formulary Edition 43

    Ministry of Health and Long-Term Care Ontario Drug Benefit Formulary/Comparative Drug Index Edition 43 Drug Programs Policy and Strategy Branch Ontario Public Drug Programs Ministry of Health and Long-Term Care Effective February 28, 2018 Visit Formulary Downloads: Edition 43 Table of Contents Part I Introduction ....................................................................................................... I.1 Part II Preamble .......................................................................................................... II.1 Part III-A Benefits List ........................................................................................... III-A.1 Part III-B Off-Formulary Interchangeable Drugs (OFI) ........................................ III-B.1 Part IV Section Currently Not In Use ......................................................................... IV Part V Index of Pharmacologic-Therapeutic Classification .................................... V.1 Part VI-A Facilitated Access - HIV/AIDS .............................................................. VI-A.1 Part VI-B Facilitated Access - Palliative Care ..................................................... VI-B.1 Part VI-C Temporary Facilitated Access - Rheumatology ................................. VI-C.1 Part VII Trillium Drug Program ................................................................................ VII.1 Part VIII Exceptional Access Program (EAP) ........................................................ VIII.1 Part IX-A Nutrition Products ................................................................................
  • Immunotherapy in Various Cancers

    Immunotherapy in Various Cancers

    © 2021 JETIR June 2021, Volume 8, Issue 6 www.jetir.org (ISSN-2349-5162) Immunotherapy in various Cancers Nirav Parmar 1st Year MSc Student Department of Biosciences and Bioengineering, IIT- Roorkee India Abstract: Immunotherapy in the metastatic situation has changed the therapeutic landscape for a variety of cancers, including colorectal cancer. Immunotherapy has firmly established itself as a new pillar of cancer treatment in a variety of cancer types, from the metastatic stage to adjuvant and neoadjuvant settings. Immune checkpoint inhibitors have risen to prominence as a treatment option based on a better knowledge of the development of the tumour microenvironment immune cell-cancer cell regulation over time. Immunotherapy has lately appeared as the most potential field of cancer research by increasing effectiveness and reducing side effects, with FDA-approved therapies for more than 10 various tumours and thousands of new clinical studies. Key Words: Immunotherapy, metastasis, immune checkpoint. Introduction: In the late 1800s, William B. Coley, now generally regarded as the founder of immunotherapy, tried to harness the ability of immune system to cure cancer for the first time. Coley began injecting live and attenuated bacteria like Streptococcus pyogenes and Serratia marcescens into over a thousand patients in 1891 in the hopes of causing sepsis and significant immunological and antitumor responses. His bacterium mixture became known as "Coley's toxin" and is the first recorded active cancer immunotherapy treatment [1]. To better understand the processes of new and traditional immunological targets, the relationship between the immune system and tumour cells should be examined. Tumours have developed ways to evade immunological responses.
  • NINDS Custom Collection II

    NINDS Custom Collection II

    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
  • A Simple Method to Measure Sulfonation in Man Using Paracetamol As Probe Drug Natália Marto 1,2*, Judit Morello1,3, Alexandra M

    A Simple Method to Measure Sulfonation in Man Using Paracetamol As Probe Drug Natália Marto 1,2*, Judit Morello1,3, Alexandra M

    www.nature.com/scientificreports OPEN A simple method to measure sulfonation in man using paracetamol as probe drug Natália Marto 1,2*, Judit Morello1,3, Alexandra M. M. Antunes3, Sofa Azeredo4, Emília C. Monteiro1,5 & Sofa A. Pereira1,5 Sulfotransferase enzymes (SULT) catalyse sulfoconjugation of drugs, as well as endogenous mediators, gut microbiota metabolites and environmental xenobiotics. To address the limited evidence on sulfonation activity from clinical research, we developed a clinical metabolic phenotyping method using paracetamol as a probe substrate. Our aim was to estimate sulfonation capability of phenolic compounds and study its intraindividual variability in man. A total of 36 healthy adult volunteers (12 men, 12 women and 12 women on oral contraceptives) received paracetamol in a 1 g-tablet formulation on three separate occasions. Paracetamol and its metabolites were measured in plasma and spot urine samples using liquid chromatography-high resolution mass spectrometry. A metabolic ratio (Paracetamol Sulfonation Index—PSI) was used to estimate phenol SULT activity. PSI showed low intraindividual variability, with a good correlation between values in plasma and spot urine samples. Urinary PSI was independent of factors not related to SULT activity, such as urine pH or eGFR. Gender and oral contraceptive intake had no impact on PSI. Our SULT phenotyping method is a simple non-invasive procedure requiring urine spot samples, using the safe and convenient drug paracetamol as a probe substrate, and with low intraindividual coefcient of variation. Although it will not give us mechanistic information, it will provide us an empirical measure of an individual’s sulfonator status. To the best of our knowledge, our method provides the frst standardised in vivo empirical measure of an individual’s phenol sulfonation capability and of its intraindividual variability.
  • 1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC

    1 Abietic Acid R Abrasive Silica for Polishing DR Acenaphthene M (LC

    1 abietic acid R abrasive silica for polishing DR acenaphthene M (LC) acenaphthene quinone R acenaphthylene R acetal (see 1,1-diethoxyethane) acetaldehyde M (FC) acetaldehyde-d (CH3CDO) R acetaldehyde dimethyl acetal CH acetaldoxime R acetamide M (LC) acetamidinium chloride R acetamidoacrylic acid 2- NB acetamidobenzaldehyde p- R acetamidobenzenesulfonyl chloride 4- R acetamidodeoxythioglucopyranose triacetate 2- -2- -1- -β-D- 3,4,6- AB acetamidomethylthiazole 2- -4- PB acetanilide M (LC) acetazolamide R acetdimethylamide see dimethylacetamide, N,N- acethydrazide R acetic acid M (solv) acetic anhydride M (FC) acetmethylamide see methylacetamide, N- acetoacetamide R acetoacetanilide R acetoacetic acid, lithium salt R acetobromoglucose -α-D- NB acetohydroxamic acid R acetoin R acetol (hydroxyacetone) R acetonaphthalide (α)R acetone M (solv) acetone ,A.R. M (solv) acetone-d6 RM acetone cyanohydrin R acetonedicarboxylic acid ,dimethyl ester R acetonedicarboxylic acid -1,3- R acetone dimethyl acetal see dimethoxypropane 2,2- acetonitrile M (solv) acetonitrile-d3 RM acetonylacetone see hexanedione 2,5- acetonylbenzylhydroxycoumarin (3-(α- -4- R acetophenone M (LC) acetophenone oxime R acetophenone trimethylsilyl enol ether see phenyltrimethylsilyl... acetoxyacetone (oxopropyl acetate 2-) R acetoxybenzoic acid 4- DS acetoxynaphthoic acid 6- -2- R 2 acetylacetaldehyde dimethylacetal R acetylacetone (pentanedione -2,4-) M (C) acetylbenzonitrile p- R acetylbiphenyl 4- see phenylacetophenone, p- acetyl bromide M (FC) acetylbromothiophene 2- -5-
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1

    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
  • WO 2017/085561 Al 26 May 20 17 (26.05.2017) W P O P C T

    WO 2017/085561 Al 26 May 20 17 (26.05.2017) W P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/085561 Al 26 May 20 17 (26.05.2017) W P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/00 (2006.01) A61K 31/415 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 47/34 (2017.01) A61P 19/02 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 9/08 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, PCT/IB2016/001815 KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (22) International Filing Date: MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 16 November 2016 (16.1 1.2016) OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 62255778 16 November 2015 (16. 11.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: MEDINCELL [FR/FR]; 1, avenue Charles TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Cros, 34830 Jacou (FR).
  • TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (Egfrt)

    TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (Egfrt)

    (19) TZZ _T (11) EP 2 496 698 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 14/71 (2006.01) C12N 9/12 (2006.01) 09.01.2019 Bulletin 2019/02 (86) International application number: (21) Application number: 10829041.2 PCT/US2010/055329 (22) Date of filing: 03.11.2010 (87) International publication number: WO 2011/056894 (12.05.2011 Gazette 2011/19) (54) TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION VERKÜRZTER REZEPTOR FÜR DEN EPIDERMALEN WACHSTUMSFAKTOR-REZEPTOR ZUR AUSWAHL UMGEWANDELTER T-ZELLEN RÉCEPTEUR DU FACTEUR DE CROISSANCE DE L’ÉPIDERME TRONQUÉ (EGFRT) POUR LA SÉLECTION DE LYMPHOCYTES T TRANSDUITS (84) Designated Contracting States: • LI ET AL.: ’Structural basis for inhibition of the AL AT BE BG CH CY CZ DE DK EE ES FI FR GB epidermal growth factor receptor by cetuximab.’ GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO CANCER CELL vol. 7, 2005, pages 301 - 311, PL PT RO RS SE SI SK SM TR XP002508255 • CHAKRAVERTY ET AL.: ’An inflammatory (30) Priority: 03.11.2009 US 257567 P checkpoint regulates recruitment of graft-versus-host reactive T cells to peripheral (43) Date of publication of application: tissues.’ JEM vol. 203, no. 8, 2006, pages 2021 - 12.09.2012 Bulletin 2012/37 2031, XP008158914 • POWELL ET AL.: ’Large-Scale Depletion of (73) Proprietor: City of Hope CD25+ Regulatory T Cells from Patient Duarte, CA 91010 (US) Leukapheresis Samples.’ J IMMUNOTHER vol. 28, no.